# Thriva

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thriva

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.thriva.co
- Total disclosed funding: $14M
- Latest round: Series A (May 22, 2020)
- Investors on record: 6

## About

Thriva Limited is a health tech company offering personalized blood testing services. Their innovative at-home blood tests empower individuals to monitor their health conveniently and receive actionable insights from healthcare professionals.Thriva Limited, founded in 2015 in London, UK, focuses on providing personalized blood testing services. The company has raised GBP 4 million in a Series A funding round on May 22, 2020, led by Target Global, with participation from Guinness Global Investors and Pembroke VCT. The funding supports their growth and service enhancements.Thriva specializes in personalized blood testing services designed to empower individuals to take control of their health and performance. Their core offering includes at-home blood tests that allow users to collect samples conveniently, which are then analyzed in accredited clinical laboratories. Upon completion of the tests, customers receive their results accompanied by detailed explanations and insights from healthcare professionals, promoting informed decision-making for health improvement. Established in 2016, Thriva has successfully assisted over 200,000 individuals across various geographical markets, including the United Kingdom and other regions where telehealth and home testing solutions are gaining traction. The company’s user-friendly digital platform enhances the customer experience, making health management accessible and relevant for modern lifestyles.Thriva generates revenue primarily through direct-to-consumer sales of its personalized blood testing services. Customers typically engage with the company by completing a health quiz that leads to the selection of a tailored blood test. Transactions are structured on a pay-per-test basis, where individuals purchase specific blood tests based on their health needs and preferences. Thriva reported a revenue of GBP 13,880,589.50 in 2023, with an EBITDA of GBP -13,338,296 for the same year.Looking ahead, Thriva plans to expand its service offerings by developing new products aimed at enhancing the health monitoring experience. The company is exploring opportunities to enter new markets, with a focus on European countries by 2025. The recent GBP 4 million raised in the Series A funding round will support these initiatives, including the launch of new testing kits and the enhancement of their digital platform.

## Funding rounds

- Series A, May 22, 2020, $4.9M — Target Global, Pembroke VCT, Guinness Global Investors
- Series A, Jul 29, 2019, $7.4M — Pembroke VCT, Guinness Global Investors
- Seed, Jul 5, 2017, $1.8M — 500 Global, Seedcamp, Funding London

## Investors

- 500 Global (https://capitalatlas.ai/funds/500-global) — Seed
- Seedcamp (https://capitalatlas.ai/funds/seedcamp) — Seed
- Funding London — Seed
- Pembroke VCT (https://capitalatlas.ai/funds/pembroke-vct) — Series A
- Guinness Global Investors (https://capitalatlas.ai/funds/guinness-global-investors) — Series A
- Target Global (https://capitalatlas.ai/funds/target-global) — Series A